Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 3, Issue 6, 2022

Results of Radiotherapy Combined with Multiple Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer

Download as PDF

DOI: 10.23977/medsc.2022.030614 | Downloads: 14 | Views: 513

Author(s)

Anqi Zhang 1, Lei Gao 1, Xiaoyan Shi 1, Wenyi Kang 1

Affiliation(s)

1 The First Affiliated Hospital of Yangtze University, Jingzhou, China

Corresponding Author

Anqi Zhang

ABSTRACT

Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers, and most of them have advanced stage, progression or metastasis at the time of diagnosis. Radiotherapy is one of the classical methods for the treatment of NSCLC. Immune checkpoint inhibitors (ICIs), the most common type of immunotherapy, have gradually developed into the preferred treatment for patients with advanced NSCLC. There are numerous clinical trials have demonstrated that radiation therapy can activate the body's immune system in the process of immune therapy, the effect of the combination of synergistic antitumor effect, can significantly improve the tumour local control, and improve the body's immune cells response "response, and through the joint model highlights the significant advantages in clinical research in China at present. However, the issues of radiotherapy dose, radiotherapy segmentation mode and timing of combined therapy are still controversial. This article reviews the mechanism, classification and distant effect of the combination of the two antitumor agents.

KEYWORDS

Non-Small Cell Lung Cancer, Radiotherapy, Immunotherapy, Immune Checkpoint Inhibitors, Remote Effect, Research Advance

CITE THIS PAPER

Anqi Zhang, Lei Gao, Xiaoyan Shi, Wenyi Kang, Results of Radiotherapy Combined with Multiple Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer. MEDS Clinical Medicine (2022) Vol. 3: 83-86. DOI: http://dx.doi.org/10.23977/medsc.2022.030614.

REFERENCES

[1] Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
[2] Alexander, M., S.Y. Kim, and H. Cheng, Update 2020: Management of Non-Small Cell Lung Cancer. Lung, 2020. 198(6): p. 897-907.
[3] Vinod, S.K. and E. Hau, Radiotherapy treatment for lung cancer: Current status and future directions. Respirology, 2020. 25 Suppl 2: p. 61-71.
[4] Wu, F., L. Wang, and C. Zhou, Lung cancer in China: current and prospect. Curr Opin Oncol, 2021. 33(1): p. 40-46.
[5] Brown, S., et al., The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol, 2019. 92(1104): p. 20190524.
[6] Chun, S.G., et al., Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol, 2017. 35(1): p. 56-62.
[7] Giaj-Levra, N., et al., Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Rev Anticancer Ther, 2020. 20(5): p. 387-402.
[8] Jonna, S. and D.S. Subramaniam, Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update. Discov Med, 2019. 27(148): p. 167-170.
[9] Vinod, S.K. and E. Hau, Radiotherapy treatment for lung cancer: Current status and future directions. Respirology, 2020. 25 Suppl 2: p. 61-71.
[10] Brown, S., et al., The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol, 2019. 92(1104): p. 20190524.
[11] Somasundaram, A., M.A. Socinski, and L.C. Villaruz, Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs, 2020. 80(9): p. 883-892.
[12] Yang, W.C., F.M. Hsu, and P.C. Yang, Precision radiotherapy for non-small cell lung cancer. J Biomed Sci, 2020. 27(1): p. 82.
[13] Kang, J., C. Zhang, and W.Z. Zhong, Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun (Lond), 2021. 41(4): p. 287-302.
[14] Soh, J., et al., Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. Cancers (Basel), 2021. 13(16).
[15] Uprety, D., et al., Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. J Thorac Oncol, 2020. 15(8): p. 1281-1297.
[16] Duma, N., R. Santana-Davila, and J.R. Molina, Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc, 2019. 94(8): p. 1623-1640.
[17] Buchbinder, E.I. and A. Desai, CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol, 2016. 39(1): p. 98-106.
[18] De Giglio, A., et al., The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines). Curr Oncol Rep, 2021. 23(11): p. 126.
[19] Hellmann, M.D., et al., Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2019. 381(21): p. 2020-2031.
[20] Xia, L., Y. Liu, and Y. Wang, PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist, 2019. 24(Suppl 1): p. S31-s41.
[21] Yang, Y., et al., Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol, 2020. 15(10): p. 1636-1646.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4534
Visits: 195295

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.